Compare JD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JD | ONC |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | China | Switzerland |
| Employees | N/A | 12000 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6B | 40.6B |
| IPO Year | 2014 | 2015 |
| Metric | JD | ONC |
|---|---|---|
| Price | $29.18 | $408.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 35 | 27 |
| Target Price | $38.93 | ★ $437.57 |
| AVG Volume (30 Days) | ★ 8.0M | 356.4K |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | $2.90 | $26.55 |
| Revenue Next Year | $5.50 | $14.91 |
| P/E Ratio | ★ $9.17 | $674.61 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $24.51 | $253.95 |
| 52 Week High | $34.30 | $388.66 |
| Indicator | JD | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 73.23 | 68.35 |
| Support Level | $28.25 | $335.44 |
| Resistance Level | $29.95 | N/A |
| Average True Range (ATR) | 0.51 | 10.85 |
| MACD | 0.41 | 2.30 |
| Stochastic Oscillator | 96.96 | 96.48 |
JD.com is the third-largest Chinese e-commerce platform by gross merchandise volume in 2025. It offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace, and omnichannel businesses.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.